Project 2: Modeling of Drug Resistance in Breast Cancer. Aim 1: Contribution of cellular heterogeneity to the development of breast cancer drug resistance to targeted Molecular Therapeutics (MT). Cancer Biology Alissa Weaver – invasion Darren Tyson – proliferation
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Aim 1: Contribution of cellular heterogeneity to the development of breast cancer drug resistance to targeted Molecular Therapeutics (MT)
Lourdes Estrada - coordination, outreach
Vito Quaranta, Director
Chemical Engineering (Vanderbilt)
Time-dependent sensitivity to MT
27% inhibition, 24h
43% inhibition, 48h
Ensemble Cell Count Data
Same as CHX at 48h but 40% less at 24h
InterMitoticTime (IMT) Data
Quiescent- Growth Model
Where is the position of oncogene-addicted cells in this high resolution landscape of cellular responses to MT?